---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-23-000117"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T06:12:10.633541+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# LianBio terminates mavacamten license for $350M; TP-03 Phase 3 shows mixed results

## Summary
- Terminated mavacamten license with BMS/MyoKardia; receives $350M payment and released from $127.5M in milestones.
- Phase 3 LIBRA trial met co-primary endpoint of mite eradication (p<0.001) but missed collarette cure (p=0.15).
- Plans to discuss TP-03 results with NMPA and expects to file NDA for Demodex blepharitis in China.
- Pro forma cash and equivalents rise to $444M (from $104M) after termination payment.

## SEC filing metadata
- accession: 0001831283-23-000117
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/lian-20231024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-23-000117
- JSON: https://secwatch.observer/filing/0001831283-23-000117.json
- Plain text: https://secwatch.observer/filing/0001831283-23-000117.txt

## Key facts
- M&A Transactions
  LianBio completed a disposition involving MyoKardia, Inc. and Bristol-Myers Squibb Company for $350 million (closed 2023-10-24).
  - Action: disposition
  - Counterparty: MyoKardia, Inc. and Bristol-Myers Squibb Company
  - Consideration: $350 million
  - Closing: 2023-10-24
  source text: Pursuant to the Termination Agreement, LianBio will receive a one-time payment of $350 million as consideration for the Transaction.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm
- Material Agreements
  LianBio terminated License Agreement with MyoKardia, Inc. and Bristol-Myers Squibb Company valued at $350 million (effective 2023-10-24).
  - Action: termination
  - Agreement: license
  - Counterparty: MyoKardia, Inc. and Bristol-Myers Squibb Company
  - Value: $350 million
  - Effective: 2023-10-24
  source text: On October 24, 2023 (the “Termination Effective Date”), LianBio entered into a Termination Agreement, dated October 24, 2023 (the “Termination Agreement”), by and among MyoKardia, Inc. (“MyoKardia”) and Bristol-Myers Squibb Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128323000117/0001831283-23-000117-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.